Gi-Young Sohn
Amministratore Delegato presso ENZYCHEM LIFESCIENCES CORPORATION
Patrimonio netto: 6 M $ in data 30/04/2024
Profilo
Gi-Young Sohn is currently the Chief Executive Officer & Director at ENZYCHEM LIFESCIENCES Corp.
since 2012.
He is also the Chairman at Bridget Lifesciences Corp.
since 2003.
Mr. Sohn has an undergraduate and graduate degree from Korea University.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 07/05/2024 | 4 069 430 ( 4.78% ) | 6 M $ | 30/04/2024 |
Posizioni attive di Gi-Young Sohn
| Società | Posizione | Inizio |
|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Amministratore Delegato | 01/06/2012 |
Bridget Lifesciences Corp.
 Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Presidente | 01/01/2003 |
Formazione di Gi-Young Sohn
| Korea University | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Health Technology |
| Aziende private | 1 |
|---|---|
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Finance |
- Borsa valori
- Insiders
- Gi-Young Sohn
